CeleCor Therapeutics

CeleCor Therapeutics Overview

Founded 2017
Status Private
Latest Deal Type Accelerator/​Inc
Investors 1

CeleCor Therapeutics General Information


Developer of a RUC-4 novel small molecule inhibitor designed to be the first point of contact treatment for STEMI. The company's molecule inhibitor uses thrombolytic agent, percutaneous coronary intervention or an αIIbβ3 antagonist that can be administered subcutaneously by auto-injector, enabling decreased mortality and later development of heart failure.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Therapeutic Devices
Other Industries
Primary Office
  • 3210 Merryfield Row
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

CeleCor Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Accelerator/Incubator Completed Startup
1. Angel (individual) 27-Apr-2017 000 Cancelled Startup

CeleCor Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
Robert Hillman President, Chief Executive Officer & Board Member
Barry Coller MD Co-Founder & Chairman, Medical & SAB
Andreas Ritzi Co-Founder & Board Member

CeleCor Therapeutics Board Members (4)

Name Representing Role Since
Andreas Ritzi CeleCor Therapeutics Co-Founder & Board Member 000 0000
Barry Coller MD CeleCor Therapeutics Co-Founder & Chairman, Medical & SAB 000 0000
Caspar Sturm CeleCor Therapeutics Board Member 000 0000
Jack Lief Self Board Member 000 0000

CeleCor Therapeutics Investors (1)

To view CeleCor Therapeutics‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
JLABS Accelerator/Incubator 000 0000 000000 0

Ready to get started?

Request a free trial